Mesoblast gets FDA nod for new potency assay to release Ryoncil batches
The company said the assay, called TIBA, will work alongside existing tests to help confirm product consistency as manufacturing evolves.
SEC filing
Latest
6 stories
Wednesday, September 23
Thursday, August 27
Mesoblast reports FY2026 revenue of $120.3 million, driven by Ryoncil launch
The company said gross profit reached $103.6 million as reported, or $109.7 million excluding amortization, while completing patient treatment in its Phase 3 back pain trial.
SEC filing
Monday, August 17
Mesoblast finishes dosing in Phase 3 trial of rexlemestrocel-L for chronic low back pain
The company enrolled and treated 350 patients in the pivotal MSB-DR004 study, setting up a mid-2027 readout.
SEC filing
Thursday, July 30
Mesoblast reports $36M quarterly Ryoncil revenue, $115M for first full year
The cell therapy maker also hit its 300-patient enrollment target in a Phase 3 back pain trial and drew down $50M more from a credit facility.
SEC filing
Monday, July 20
Mesoblast CEO Itescu exercises options, boosting stake to over 80.8 million shares
Silviu Itescu paid A$2,733,734 to exercise options, according to a company filing dated July 21, 2026.
SEC filing
Tuesday, July 14
Mesoblast enrolls 300th patient in Phase 3 back pain trial of rexlemestrocel-L
The company said commercial manufacturing is underway in parallel while it awaits results expected in mid-2027.
SEC filing